Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Learn how the benefits of GLP-1s may be outweighed by the risks.

The two largest health insurers in Massachusetts are effectively telling the drug companies that they may seek a rapidly ...

GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...

This is only a glimpse of the data available to CivicScience clients. Discover more data. It’s safe to say that GLP-1 ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

Hims & Hers will begin offering generic semaglutide drugs in Canada next year after Novo Nordisk lost its exclusive patent ...

A new study reveals that weight lost with GLP-1 drugs, such as semaglutide, is regained within a year after stopping ...

Consumers are becoming more concerned about their health, with many prioritising weight loss. But what do they consider to be ...

Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?

Temperature-controlled packaging solutions provider Nordic Cold Chain Solutions has introduced what it claims to be the first cold chain packaging solution tailored for transporting glucagon-like ...